A randomized, controlled trial comparing twiee-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine hagedorn (NPH) therapy in newly diagnosed type 1 diabetes

Pediatrics

Volumn 121, Issue 3, 2008, Pages

  Hassan, Krishnavathana ^a   Rodriguez, Luisa M ^a   Johnson, Susan E ^a   Tadlock, Susanne ^a   Heptulla, Rubina A ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Texas Children's Hospital   (United States)

Author keywords

Children; Diabetes; Insulin

Indexed keywords

GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; INSULIN ASPART; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; DRUG DERIVATIVE; GLARGINE; LONG ACTING INSULIN; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; BODY MASS; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MIXTURE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; ADULT; BLOOD GLUCOSE MONITORING; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG COMBINATION; FOLLOW UP; HOSPITALIZATION; PROBABILITY; PROSPECTIVE STUDY; QUALITY OF LIFE; REFERENCE VALUE; RISK ASSESSMENT; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; CHILD; DIABETES MELLITUS, TYPE 1; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIA; INJECTIONS, SUBCUTANEOUS; INSULIN; INSULIN, ISOPHANE; INSULIN, LONG-ACTING; MALE; PROBABILITY; PROSPECTIVE STUDIES; QUALITY OF LIFE; REFERENCE VALUES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 40949133422     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2007-1679     Document Type: Article

References (34)

1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin- dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329(14): 977-986
2. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes. 1996;45(10):1289-1298
3. Wagner JA. Response shift and glycemic control in children with diabetes. Health Qual Life Outcomes. 2005;3(1):38
4. Liebl A. Challenges in optimal metabolic control of diabetes. Diabetes Metab Res Rev. 2002; 18(suppl 3):S36-S41
5. Griffen SC, Oostema K, Stanhope KL, et al. Administration of Lispro insulin with meals improves glycemic control, increases circulating leptin, and suppresses ghrelin, compared with regular/NPH insulin in female patients with type 1 diabetes. J Clin Endocrinol Metab. 2006;91 (2):485-491
6. Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000;49(12):2142-2148
7. Bode BW, Tamborlane WV, Davidson PC. Insulin pump therapy in the 21st century: strategies for successful use in adults, adolescents, and children with diabetes. Postgrad Med. 2002; 111 (5):69-77; quiz 27
8. Bolli GB. Rationale for using combinations of short-acting in-sulin analogue and NPH insulin at mealtime in the treatment of type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 1999; 12(suppl 3):737-744
9. Bolli GB, Di Marchi RD, Park GD, Pramming S, Koivisto VA. Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia. 1999;42(10):1151-1167
10. Abbott MB, Levin RH. What's new: newly approved drugs for children. Pediatr Rev. 2001;22(10):357-359
11. Wang F, Carabino JM, Vergara CM. Insulin glargine: a systematic review of a long-acting insulin analogue. Clin Ther. 2003; 25(6):1541-1577, discussion 1539-1540
12. Home PD, Ashwell SG. An overview of insulin glargine. Diabetes Metab Res Rev. 2002; 18(suppl 3):S57-S63
13. Ashwell SG, Gebbie J, Home PD. Twice-daily compared with once-daily insulin glargine in people with type 1 diabetes using meal-time insulin aspart. Diabet Med. 2006;23(8):879-886
14. Fiallo-Scharer R, Horner B, McFann K, Walravens P, Chase HP. Mixing rapid-acting insulin analogues with insulin glargine in children with type 1 diabetes mellitus. J Pediatr. 2006;148(4): 481-484
15. Kaplan W, Rodriguez LM, Smith OE, Haymond MW, Heptulla RA. Effects of mixing glargine and short-acting insulin analogs on glucose control. Diabetes Care. 2004;27(11 ):2739-2740
16. Tamborlane WV, Kollman C, Steffes MW, et al. Comparison of fingerstick hemoglobin Alc levels assayed by DCA 2000 with the DCCT/EDIC central laboratory assay: results of a Diabetes Research in Children Network (DirecNet) Study. Pediatr Diabetes. 2005;6 (1):13-16
17. Varni JW, Burwinkle TM, Jacobs JR, Gottschalk M, Kaufman F, Jones KL. The PedsQL in type 1 and type 2 diabetes: reliability and validity of the Pediatric Quality of Life Inventory Generic Core Scales and Type 1 Diabetes Module. Diabetes Care. 2003;26(3):631-637
18. Varni JW, Seid M, Kurtin PS. PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. Med Care. 2001;39(8):800-812
19. Varni JW, Seid M, Rode CA. The PedsQL: measurement model forthe pediatric quality of life inventory. Med Care. 1999:37(2): 126-139
20. Fulcher GR, Gilbert RE, Yue DK. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy. Intern Med J. 2005;35(9):536-542
21. Murphy NP, Keane SM, Ong KK, et al. Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens. Diabetes Care. 2003;26(3):799-804
22. Raskin P, Klaff L, Bergenstal R, Halle JP, Donley D, Mecca T. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care. 2000; 23(11):1666-1671
23. Garg SK, Gottlieb PA, Hisatomi ME, et al. Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine. Diabetes Res Clin Pract. 2004;66(l):49-56
24. Chase HP, Dixon B, Pearson J, et al. Reduced hypoglycemic episodes and improved glycemic control in children with type 1 diabetes using insulin glargine and neutral protamine Hagedorn insulin, J Pediatr. 2003;143(6):737-740
25. Garg SK, Paul JM, Karsten JI, Menditto L, Gottlieb PA. Reduced severe hypoglycemia with insulin glargine in intensively treated adults with type 1 diabetes. Diabetes Technol Ther. 2004; 6(5):589-595
26. Jackson A, Ternand C, Brunzell C, et al. Insulin glargine improves hemoglobin Alc in children and adolescents with poorly controlled type 1 diabetes. Pediatr Diabetes. 2003;4(2): 64-69
27. Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care. 2000;23(5):639-643
28. Rosenstock J, Dailey G, Massi-Benedetti M, Fritsche A, Lin Z, Salzman A. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care. 2005;28(4):950-955
29. Hamann A, Matthaei S, Rosak C, Silvestre L. A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes. Diabetes Care. 2003;26(6):1738-1744
30. Holl RW, Swift PG, Mortensen HB, et al. Insulin injection regimens and metabolic control in an international survey of adolescents with type 1 diabetes over 3 years: results from the Hvidore study group. Eur J Pediatr. 2003;]62(l):22-29
31. Mortensen HB, Villumsen J, Volund A, Petersen KB, Nerup J. Relationship between insulin injection regimen and metabolic control in young Danish type 1 diabetic patients. The Danish Study Group of Diabetes in Childhood. Diabet Med. 1992;9(9): 834-839
32. Huizinga MM, Shintani A, Michon S, et al. A randomized controlled trial to prevent glycemic relapse in longitudinal diabetes care: study protocol (NCT00362193). Implement Sei. 2006;1(1):24
33. Diabetes Control and Complications Trial Research Group. Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes. 1997;46(2):271-286
34. Owens DR, Griffiths S. Insulin glargine (Lantus). Int J Clin Pract. 2002;56(6):460-466